Recent advances in targeted therapy for pancreatic adenocarcinoma
作者机构：Department of Medical OncologyNational Cancer Center/National Clinical Research Center for Cancer/Cancer HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing 100021China Department of Medical OncologyNational Cancer Center/National Clinical Research Center for Cancer/Hebei Cancer HospitalChinese Academy of Medical SciencesLangfang 065001Hebei ProvinceChina
出 版 物：《World Journal of Gastrointestinal Oncology》 (世界胃肠肿瘤学杂志（英文版）（电子版）)
年 卷 期：2023年第15卷第4期
页 面：571-595页
核心收录：
学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
基 金：Supported by The National Key Research and Development Program of China,No.2021YFF1201300 The Special Foundation of Wu Jieping Medical Foundation for Clinical Scientific Research,No.320.6750.2022-10-95
主 题：Pancreatic carcinoma Targeted therapy Cancer stem cell Monoclonal antibody Epigenetic modifier
摘 要：Pancreatic adenocarcinoma(PDAC)is a fatal disease with a 5-year survival rate of 8%and a median survival of 6 *** PDAC,several mutations in the genes are involved,with Kirsten rat sarcoma oncogene(90%),cyclin-dependent kinase inhibitor 2A(90%),and tumor suppressor 53(75%–90%)being the most *** against decapentaplegic homolog 4 represents 50%.In addition,the selfpreserving cancer stem cells,dense tumor microenvironment(fibrous accounting for 90%of the tumor volume),and suppressive and relatively depleted immune niche of PDAC are also constitutive and relevant elements of *** targeted therapy is widely utilized and effective in several solid *** PDAC,targeted therapy has been extensively evaluated;however,survival improvement of this aggressive disease using a targeted strategy has been *** is currently only one United States Food and Drug Administration-approved targeted therapy for PDAC–erlotinib,but the absolute benefit of erlotinib in combination with gemcitabine is also minimal(2 wk).In this review,we summarize current targeted therapies and clinical trials targeting dysregulated signaling pathways and components of the PDAC oncogenic process,analyze possible reasons for the lack of positive results in clinical trials,and suggest ways to improve *** also discuss emerging trends in targeted therapies for PDAC:combining targeted inhibitors of multiple *** PubMed database and National Center for Biotechnology Information clinical trial website(***)were queried to identify completed and published(PubMed)and ongoing(***)clinical trials(from 2003-2022)using the keywords pancreatic cancer and targeted *** PubMed database was also queried to search for information about the pathogenesis and molecular pathways of pancreatic cancer using the keywords pancreatic cancer and molecular pathways.
维普期刊数据库